Novo Nordisk’s diabetes pill clears cardiac safety hurdle

Novo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase 3 trial assessing its cardiac safety, with results showing it also reduced risk of cardiovascular and all-causes death in high-risk patients. The double blind https://pharmaphorum.com/news/novos-diabetes-pill-clears-cardiac-safety-hurdle-filings-to-follow/